<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guaifenesin and pseudoephedrine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guaifenesin and pseudoephedrine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Guaifenesin and pseudoephedrine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12524" href="/d/html/12524.html" rel="external">see "Guaifenesin and pseudoephedrine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="140725" href="/d/html/140725.html" rel="external">see "Guaifenesin and pseudoephedrine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F177863"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Altarussin-PE [OTC];</li>
<li>CVS Mucus D Extended Release [OTC];</li>
<li>Entex T [OTC] [DSC];</li>
<li>FT Mucus Relief D 12 Hour [OTC];</li>
<li>Maxifed [OTC];</li>
<li>Mucinex D Max Strength [OTC];</li>
<li>Mucinex D [OTC];</li>
<li>Mucus Relief D [OTC];</li>
<li>Poly-Vent IR [OTC];</li>
<li>Rydex G [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F177879"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha-/Beta- Agonist;</li>
<li>
                        Expectorant</li></ul></div>
<div class="block doa drugH1Div" id="F177867"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">Also refer to specific product labeling.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4d8d584-ffb3-450f-adf3-db72cfcc649f">Expectorant/decongestant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Expectorant/decongestant:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (Entex T): Guaifenesin 375 mg/pseudoephedrine 60 mg every 4 hours (maximum: Guaifenesin 1,500 mg/pseudoephedrine 240 mg/24 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (Maxifed): Guaifenesin 360 mg/pseudoephedrine 60 mg every 4 hours (maximum: Guaifenesin 1,440 mg/pseudoephedrine 240 mg/24 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, extended release (Mucinex D, Mucinex D Maximum Strength): Guaifenesin 1,200 mg/pseudoephedrine 120 mg every 12 hours (maximum: Guaifenesin 2,400 mg/pseudoephedrine 240 mg/24 hours)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990347"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987715"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F177868"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block dop drugH1Div" id="F177875"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="140725" href="/d/html/140725.html" rel="external">see "Guaifenesin and pseudoephedrine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Safety and efficacy for the use of cough and cold products in infants and young children is limited; the AAP warns against the use of these products for respiratory illnesses in infants and young children; the FDA does not recommend OTC use in infants and children &lt;2 years of age due to the risk of serious and life-threatening adverse effects (including death) and recommends to use with caution in pediatric patients ≥2 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fa6b0ba-dd7f-4b66-9ad5-b3e294ceeb63">Cough and upper respiratory symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cough</b>
<b> and upper respiratory symptoms (expectorant/decongestant)</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 360 mg and pseudoephedrine 60 mg (eg, Maxifed):</p>
<p style="text-indent:-2em;margin-left:8em;">Children 6 to &lt;12 years: Oral: <sup>1</sup>/<sub>2</sub> tablet every 4 hours as needed; maximum daily dose: 2 tablets per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 1 tablet every 4 hours as needed; maximum daily dose: 4 tablets per <b>24 hours</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablets:</p>
<p style="text-indent:-2em;margin-left:6em;">Guaifenesin 1,200 mg and pseudoephedrine 120 mg (eg, Mucinex D):</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 1 tablet every 12 hours as needed; maximum daily dose: 2 tablets per <b>24 hours</b>.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112859"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. See individual agents.</p></div>
<div class="block dohp drugH1Div" id="F51112860"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. See individual agents.</p></div>
<div class="block adr drugH1Div" id="F177846"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block coi drugH1Div" id="F177857"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F177843"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be more sensitive to adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Safety and efficacy have not been established in children &lt;2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F57828814"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported (in some cases, high blood concentrations of pseudoephedrine were found). Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age, and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018). Multiple concentrations of oral liquid formulations exist; close attention must be paid to the concentration when ordering or administering.</p></div>
<div class="block foc drugH1Div" id="F177851"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Altarussin-PE: Guaifenesin 100 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (240 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Altarussin-PE: Guaifenesin 100 mg and pseudoephedrine hydrochloride 30 mg per 5 mL (118 mL) [alcohol free; contains fd&amp;c red #40 (allura red ac dye), menthol, saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entex T: Guaifenesin 375 mg and pseudoephedrine hydrochloride 60 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxifed: Guaifenesin 360 mg and pseudoephedrine hydrochloride 60 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucus Relief D: Guaifenesin 400 mg and pseudoephedrine hydrochloride 40 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Poly-Vent IR: Guaifenesin 380 mg and pseudoephedrine hydrochloride 60 mg [gluten free; contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rydex G: Guaifenesin 398 mg and pseudoephedrine hydrochloride 38.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Guaifenesin 375 mg and pseudoephedrine hydrochloride 60 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CVS Mucus D Extended Release: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Mucus Relief D 12 Hour: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex D: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex D Max Strength: Guaifenesin 1200 mg and pseudoephedrine hydrochloride 120 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucus Relief D: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Guaifenesin 1200 mg and pseudoephedrine hydrochloride 120 mg, Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg</p></div>
<div class="block geq drugH1Div" id="F177840"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323175"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Tusnel Pediatric Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5-50 mg/mL (per mL): $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Mucinex D Max Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120-1200 mg (per each): $2.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Mucinex D Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60-600 mg (per each): $0.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Pseudoephedrine-guaiFENesin ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60-600 mg (per each): $0.48 - $0.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120-1200 mg (per each): $0.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Maxifed Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60-360 mg (per each): $0.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Poly-Vent IR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60-380 mg (per each): $0.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F177854"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not crush, chew, or break ER formulations. May interfere with sleep; administering some products a few hours before bedtime may help minimize insomnia. Take with full glass of water.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR tablet, capsule, or oral solution. Scored ER tablets can be cut in half but not crushed. ER capsules may be opened and sprinkled onto soft food of choice as long as patient swallows mixture without biting down or chewing.</p></div>
<div class="block admp drugH1Div" id="F52612952"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals; take with full glass of water. Extended-release formulations should not be broken, crushed, or chewed.</p></div>
<div class="block use drugH1Div" id="F177853"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Expectorant/decongestant:</b> Temporary relief of nasal/sinus congestion and sinus pressure by promoting nasal/sinus drainage associated with common cold, hay fever, or upper respiratory allergies; loosens mucus and thins bronchial secretions making coughs more productive; temporarily restores freer breathing through the nose</p></div>
<div class="block mst drugH1Div" id="F177886"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entex may be confused with Tenex </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Entex LA brand name represents a different product in the U.S. than it does in Canada. In the U.S., Entex LA contains guaifenesin and phenylephrine, while in Canada the product bearing this brand name contains guaifenesin and pseudoephedrine. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mucinex D may be confused with Mucinex DM</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299427"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F177847"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha-/Beta-Agonists (Indirect-Acting) may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May diminish the therapeutic effect of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F177859"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs.</p></div>
<div class="block brc drugH1Div" id="F177860"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs.</p></div>
<div class="block phk drugH1Div" id="F177856"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F177861"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Guafedrin | Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Robitussin d | Robitussin pe</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Phensedyl chesty family cough</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Coftex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dimetapp nf</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Compound pseudoephedrine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Robitussin pe</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Robitussin pe | Theraflu EP</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Iniston mucosidad y congestion</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benylin mucus cough plus decongestant | Boots cough and decongestant syrup 6 years plus | Robitussin chesty cough with congestion</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Robitussin pe</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Sudafed expectorant | Zerofed</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Actifed chesty n/d | Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sinufed</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Robitussin pe | Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Robitussin severe congestion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Benadryl chesty</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ammofed | Triaminic chest</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aldex Gs | Amitex pse | Aquatab d | Centex-Pse | Congestac | Conpec LA | Deco-d | Decongestant ii | Deconsal ii | Desal-Ii | Drituss gp | Duraphen | Durasal ii | Duratuss | Duratuss am/pm | Duratuss gp | Entex pse | Entex T | Exefen | G-Phed | G-Phed-PD | Gfn/Pse | Gp 1200/75 | Guaifed | Guaifenesin &amp; pseudoephedrine hcl er | Guaifenesin and pseudoephedrine hcl | Guaifenesin and pseudoephedrine hydrochloride | Guaifenesin-p-pd | Guaifenex pse 80 extended release | Guaifenex rx | Guaimax-d | Guaipax pse | Guiadrine gp | Guiadrine pse | Iosal ii | Iotex PSE | Liquibid-pd | Maxifed | Medent ld | Medent-Ldi | Mintab d | Miraphen PSE | Panmist la | Profen ii | Pseudoephedrine hcl 60mg guaifenesin 375mg | Pseudofen-PD | Pseudofenesin PSE | Pseudovent | Pseudovent ped | Respa 1st | Respaire | Respaire-60 | Rydex g | S-pak | Stamoist e | Sudal | Sudatex G | Syn rx | Tuss LA | Tussin pe | Zephrex | Zephrex la</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bronex | Guafedrin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bioflu expectorant</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Guafedrin | Robitussin pe</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Robitussin Cold | Robitussin pe | Robitussin Severe | Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Maxasin | Meditussin | Robitussin ps | Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Eksofed Ekspektoran | Rinogest Ekspektoran | Sudafed expectorant</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Actifed wet cough</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. Available at http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guaifenesin-and-pseudoephedrine-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Entex T (guaifenesin and pseudoephedrine hydrochloride tablet) [prescribing information]. Ridgeland, MS: WraSer Pharmaceuticals, LLC.; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. Available at <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed January 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. Available at <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed January 24, 2023.</div>
</li>
<li>
<div class="reference">
                  Guaifenesin and pseudoephedrine hydrochloride tablet, extended release [prescribing information]. Lawrenceville, NJ: Aurohealth LLC; April 2021.</div>
</li>
<li>
<div class="reference">
                  Maxifed (guaifenesin and pseudoephedrine hydrochloride tablet) [prescribing information]. Brooksville, FL: MCR American Pharmaceuticals; January 2018.</div>
</li>
<li>
<div class="reference">
                  Mucinex D (guaifenesin and pseudoephedrine hydrochloride tablet, extended release) [prescribing information]. Parsippany, NJ: Reckitt Benckiser, LLC.; July 2012.</div>
</li>
<li>
<div class="reference">
                  Mucinex D Maximum Strength (guaifenesin and pseudoephedrine hydrochloride tablet, extended release) [prescribing information]. Parsippany, NJ: RB Health (US); received May 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8963 Version 254.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
